During March, Michiganders are just a phone call or a click away from getting a free at-home screening test for the nation’s third-most diagnosed cancer from McLaren Cancer Institute during National Colorectal Cancer Awareness Month.
Everist Genomics, a rapidly growing personalized medicine company, today announced the launch of the world’s first comprehensive companion diagnostics and prognostics portfolio to improve early diagnosis, management and treatment of patients with colorectal cancer.
According to research, elevated blood sugar levels are associated with an increased risk of colorectal cancer.
Ann Arbor-based Everist Genomics announced the worldwide commercial availability of its OncoDefender-CRC colorectal cancer assay, the first and only molecular prognostic test capable of accurately predicting the risk of recurrence of cancer in patients previously treated […]
Botsford Hospital Cancer Center will offer FREE colorectal cancer screening this Saturday.
Bankole Thompson joins the roundtable. Plus an update on colorectal cancer month from Dr. Gregory Olds.
Colorectal cancer screening. Just the thought of it makes most people feel uneasy and embarrassed. But experts at the University of Michigan Comprehensive Cancer Center say choosing to ignore it could cost you your life.
Ann Arbor-based Everist Genomics said Monday that it had received United States Clinical Laboratory Improvement Amendment certification to launch its OncoDefender-CRC assay, a prognostic test for assessing the risk of cancer recurrence for patients with early stage colorectal cancer.
Ann Arbor-based Everist Genomics, a company developing gene-based molecular assays for the prediction of cancer recurrence, last week announced the positive results of the first external validation study of its OncoDefender-CRC colorectal cancer recurrence test.
The University of Michigan Comprehensive Cancer Center has received a five-year $10.7 million grant from the National Cancer Institute to study colorectal and pancreatic cancer.